<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3F44A826-2E41-44F7-BC63-CD77520FE8F3"><gtr:id>3F44A826-2E41-44F7-BC63-CD77520FE8F3</gtr:id><gtr:name>Valiseek Ltd</gtr:name><gtr:address><gtr:line1>24 GREVILLE STREET , GREVILLE STREET</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>EC1N 8SS</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3F44A826-2E41-44F7-BC63-CD77520FE8F3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>3F44A826-2E41-44F7-BC63-CD77520FE8F3</gtr:id><gtr:name>Valiseek Ltd</gtr:name><gtr:address><gtr:line1>24 GREVILLE STREET , GREVILLE STREET</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>EC1N 8SS</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>215081.0</gtr:offerGrant><gtr:projectCost>477959.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/77B245CD-ACE1-442D-9B80-2BFD8798E8A5"><gtr:id>77B245CD-ACE1-442D-9B80-2BFD8798E8A5</gtr:id><gtr:firstName>Suzanne</gtr:firstName><gtr:surname>Dilly</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=720370"><gtr:id>C2C3E8FF-7B31-480E-A498-527DE1A07BF5</gtr:id><gtr:title>Tangent Reprofiling. Development of prototype: TAN2004, a safe, known drug formulated for treatment of prostate and lung cancer.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Development of Prototype</gtr:grantCategory><gtr:grantReference>720370</gtr:grantReference><gtr:abstractText>Some cancerous tumors require, or grow faster in the presence of, steroid hormones such as
estrogen or testosterone. These cancers can be treated by chemotherapy drugs to prevent the
tumor using hormones found naturally in the body. Many of these drugs work by blocking the
receptors for the hormone on the outside edges of the tumor, starving the tumor by preventing
it from recognizing the hormone. However, many hormone-dependant tumors develop
resistance to these drugs by learning to make the hormones internally.
We used our proprietary technology to study drugs that are currently used in non-cancer
diseases. One drug was identified as being capable of preventing internal hormone production
by tumors. This drug is already in clinical use for an alternative disease which requires long
term use, so the safety and side effects are already well characterized across a broad
population of patients. We propose combining this drug with a common, safe nutritional
supplement to attack the tumor from within while maintaining the starvation procedure
described above.
We already have data to demonstrate a reduction in growth of prostate cancer cells with the
drug in vitro, and preliminary efficacy data for prostate tumors in mice, however, we now
need to expand this to optimise the prototype drug combination formulation and dosing
schedule. We also look to expand the use into lung cancer, for which we have already seen
promising in vitro data. This project includes a first in vivo lung cancer model as well as
advanced stage prostate cancer mouse models.
This project period will develop our prototype cancer treatment from proof of concept to
clinic-ready, ensuring partnering for clinical development is likely on conclusion.
We believe this offers an exciting opportunity to prolong successful treatment of a range of
common cancers including prostate and lung cancer.</gtr:abstractText><gtr:fund><gtr:end>2015-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>215081</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">720370</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>